Browse TRABD2B

Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF01963 TraB family
Function

Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. Able to cleave WNT3A, WNT5, but not WNT11. Required for head formation.

> Gene Ontology
 
Biological Process GO:0016055 Wnt signaling pathway
GO:0018158 protein oxidation
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031334 positive regulation of protein complex assembly
GO:0032459 regulation of protein oligomerization
GO:0032461 positive regulation of protein oligomerization
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0051259 protein oligomerization
GO:0198738 cell-cell signaling by wnt
GO:1904806 regulation of protein oxidation
GO:1904808 positive regulation of protein oxidation
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0008237 metallopeptidase activity
GO:0017147 Wnt-protein binding
Cellular Component GO:0031300 intrinsic component of organelle membrane
GO:0031301 integral component of organelle membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRABD2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRABD2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRABD2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1960.275
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.310.484
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1110.769
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7510.254
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7550.642
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7440.699
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0620.916
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3490.689
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.390.662
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5670.673
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7030.701
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8720.000646
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRABD2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRABD2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRABD2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRABD2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRABD2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRABD2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRABD2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRABD2B
NameTraB domain containing 2B
Aliases TIKI2; TRAB domain-containing protein 2B; UPF0632 protein A; heart, kidney and adipose-enriched transmembran ......
Chromosomal Location1p33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRABD2B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.